Hubei Goto Biopharm Co.Ltd.
Hubei Goto Biopharm Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other pharmaceutical raw materials. The company was founded in 2006 and is based in Xiangyang, China.
Hubei Goto Biopharm Co.Ltd. (300966) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.000x
Based on the latest financial reports, Hubei Goto Biopharm Co.Ltd. (300966) has a cash flow conversion efficiency ratio of 0.000x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-373.11K) by net assets (CN¥957.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hubei Goto Biopharm Co.Ltd. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Hubei Goto Biopharm Co.Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hubei Goto Biopharm Co.Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hubei Goto Biopharm Co.Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang East Asia Pharmaceutical Co. Ltd.
SHG:605177
|
-0.008x |
|
LUBAWA SA
WAR:LBW
|
0.058x |
|
Bajaj Hindusthan Sugar Limited
NSE:BAJAJHIND
|
-0.007x |
|
agilon health Inc
NYSE:AGL
|
-0.162x |
|
Guangdong AVCiT Tech Hldg Co
SHE:001229
|
0.026x |
|
Anika Therapeutics Inc
NASDAQ:ANIK
|
0.032x |
|
Addcn Technology Co Ltd
TWO:5287
|
0.103x |
|
Loandepot Inc
NYSE:LDI
|
0.100x |
Annual Cash Flow Conversion Efficiency for Hubei Goto Biopharm Co.Ltd. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Hubei Goto Biopharm Co.Ltd. from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.01 Billion | CN¥-20.59 Million | -0.020x | -130.49% |
| 2023-12-31 | CN¥1.02 Billion | CN¥68.13 Million | 0.067x | +371.65% |
| 2022-12-31 | CN¥981.14 Million | CN¥-24.04 Million | -0.024x | -134.99% |
| 2021-12-31 | CN¥828.42 Million | CN¥58.00 Million | 0.070x | +180.51% |
| 2020-12-31 | CN¥539.85 Million | CN¥13.47 Million | 0.025x | +41.28% |
| 2019-12-31 | CN¥481.25 Million | CN¥8.50 Million | 0.018x | +115.06% |
| 2018-12-31 | CN¥408.26 Million | CN¥-47.89 Million | -0.117x | -59.78% |
| 2017-12-31 | CN¥300.45 Million | CN¥-22.06 Million | -0.073x | -- |